Respiratory

Smartphone app-based interventions were found to be more effective when combined with pharmacotherapy.

Applications which utilize social media appear to reduce smoking relapse rates.

The approval follows a unanimous vote of support from the FDA Antimicrobial Drugs Advisory Committee.

Researchers encourage physicians to personalize care plans to ensure that more patients adhere to their inhalers.

Electronic inhaler devices record objective inhalation quality data and permit assessment of patient efforts.

The first RSV vaccines were approved by the FDA earlier this year.

A recent study examined the effects that different work environments can have on adults with asthma.

Which masks (if any) serve as the best protection against wildfire smoke, and what do experts say about home appliances like air conditioners?

Air quality in New York City was the worst in the world on Tuesday morning.

Knowledge gaps exist around the timing of pneumonitis onset in patients treated with checkpoint inhibitors.

Abrysvo is the second RSV vaccine approved by the FDA.

Exhaled carbon monoxide in vape users significantly decreased between their first and third clinical visits.

Some patients with PAH need to travel long distances, which may impact their access to quality care providers.

A higher dose of the carbonic anhydrase inhibitor does not seem to provide any additional improvements.

Relocation led to a reduction in asthma exacerbations, exceeding the effect of inhaled corticosteroids, and was similar to biologic agents.

The trial also revealed that nirsevimab reduced the incidence of hospitalizations due to severe RSV-related LRTD by 75.1%.

The vaccine is approved for use in adults aged 60 and older to prevent lower respiratory tract disease caused by RSV.

How much does education about the specific risks of smoking assist in smoking cessation?

Two RSV vaccines for seniors have completed phase 3 trials and demonstrated beneficial results. The public still awaits FDA decisions on potential approvals for both.

Cedar pollen allergen-specific IgE values may be sufficient for diagnostic use in pollen allergy screening.

Data suggest a high rate of secondary bacterial ventilator-associated pneumonia in patients with COVID-19 and acute respiratory distress syndrome.

The FDA granted the EUA based on the phase 3 trial results that demonstrated vilobelimab's efficacy compared to placebo, with a 23.9% relative reduction in all-cause mortality from COVID-19 at 28 days.

The effects of complex interactions with pollens, meteorological variables, and air pollutants on the concentration of pollen in a changing climate is still not well understood.